Related Experiment Video
Updated: Oct 14, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Migration Characteristics and Mechanism of Active Components From Jieyu Anshen Granule in Different Insomnia Mouse
Shiqi Yan1, Mengting Lu1, Ping Sun2
1Department of Dermatology and Venereology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China.
Rationale:
Insomnia is a highly prevalent disorder with substantial health and socioeconomic impacts, for which traditional Chinese medicine is an important treatment option. Jieyu Anshen Granule (JYAS-G) shows excellent clinical efficacy in insomnia treatment, but its active components, in vivo migration characteristics and underlying mechanisms remain unclear.
Methods:
Two mouse insomnia models induced by p-chlorophenylalanine (PCPA, chemical method) and sleep deprivation machine (SDM, physical method) were established respectively, and mice were administered with low and high doses of JYAS-G, with open field test used to evaluate the pharmacodynamic effects. UHPLC-Q-Orbitrap-MS combined with GNPS was applied to systematically identify the in vitro components of JYAS-G and its migration profiles in mouse plasma, liver, heart, prefrontal cortex, hippocampus, and hypothalamus.
Results:
The SDM model induced insomnia with manic-like behaviors, which were significantly ameliorated by JYAS-G, whereas the PCPA model produced no significant insomnia-like phenotypes under the current conditions. In total, 89 in vitro components and 43 blood-absorbed components of JYAS-G were identified, showing marked tissue-specific distribution. Network pharmacology and molecular docking identified core components, including furanogermenone and curcumenol, predicted to exert anti-insomnia effects by targeting ADORA2A, GABRB3, and SLC6A4 and regulating the neuroactive ligand-receptor interaction pathway.
Conclusions:
This study characterizes the in vivo migration characteristics of JYAS-G and provides insights into its multi-target anti-insomnia mechanism, while comparing the modeling differences between two common insomnia animal models. These findings provide scientific evidence for the rational clinical application and further development of JYAS-G.
Related Concept Videos
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
